Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
Ross Silver has been advising, researching and investing in public companies across all industries throughout his career. Prior to founding Vista Partners LLC in 2005, Silver served as a research analyst for a San Francisco-based hedge fund. From 2000 to 2003, Silver served as a research associate covering consumer discretionary and consumer staple companies at Dresdner RCM (now Allianz). Prior to joining Dresdner RCM, Silver was a member of CIBC's Technology, Media, and Telecom Investment Banking group, where he assisted with equity and debt offerings. Silver holds a bachelor's degree in business economics from the University of California, Santa Barbara. He has served as a consultant for government agencies including the National Institutes of Health (NIH). He holds a Series 65 Securities license.
Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy (12/6/12) Many components go into building a successful biotech company, but excellent management is a keystone. Combine good management with an innovative product or service, and investors can possibly unlock big multiples over their original investments. So says Principal Analyst and Fund Manager Ross Silver, co-founder of Vista Partners. In this interview with The Life Sciences Report, Silver brings obscure micro-cap ideas to life and discusses why they may have mammoth potential.
"OCLS has an alternative to antibiotics, and it won't cause resistant bacteria to evolve. That's what's so exciting." (12/6/12) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Ross Silver More >
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >